Quince Therapeutics

Update in progress

QNCX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Quince Therapeutics, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing therapies for debilitating and rare diseases. Its lead candidate, EryDex, targets pediatric neurodegenerative conditions such as A-T, caused by ATM gene mutations. The AIDE platform uses automated processes to encapsulate a drug into a patient’s red blood cells, with a sterile treatment kit. Formerly Cortexyme, based in South San Francisco, founded in 2012.

Company score

Sentiment: -0.15; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.09; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.07; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive